## Revised Exhibit AL Wraparound Services/Transition to Independence Services

<u>Section 1. Overview</u>: The Network Provider is funded to provide Wraparound services and/or Transition to Independence Process (TIP) model services (collectively referred to as "Program Services") to youth and young adults 14-25 years old, and their families, with serious emotional disturbances (SED), or those who experience early onset SED/severe mental illness (SMI).

The Wraparound model is described in **Exhibit T, Children's Mental Health Services Model – Families and Communities Empowered for Success (F.A.C.E.S.)**.

The TIP service model prepares its participants for transition into adult roles through an individualized process, engaging them in the process of planning for future, as well as providing developmentally-appropriate and appealing supports and services (Clark & Hart, 2009). The TIP Model™ involves youth and young adults in a process that facilitates their movement towards greater self-sufficiency and successful achievement of their goals. Young people are encouraged to explore their interests and futures as related to each of the transition domains: employment and career, education, living situation, personal effectiveness and wellbeing, and community-life functioning. The TIP system also supports and involves family members and other informal key players as relevant in meeting their needs and those of the young person.

The Network Provider must adhere to the service delivery described in the ME's FACES service model policy and procedure and the ME's Children's System of Care Service Model policy and procedure, herein incorporated by reference and available upon request.

<u>Section 2. Minimum Numbers to be Served in TIP Services</u>: The Network Provider must enroll a minimum of <u>15</u> youth and/or young adults into the TIP model services.

<u>Section 3. Minimum Numbers to be Served for Wraparound Services:</u> The Network Provider must enroll a minimum of <u>15</u> youth and/or young adults currently receiving Wraparound into the TIP services described in this exhibit.

<u>Section 4. Performance Specifications</u>: The Network Provider shall collect and submit performance data and individual outcomes to the ME's data system in compliance with FASAMS DCF Pamphlet 155-2 on persons served under this grant. The standards and outcomes are listed in **Exhibit D**, **Substance Abuse and Mental Health Required Performance Outcomes/Outputs** and shall be collected and reported as appropriate.

<u>Section 5. Data Reporting and Coding Instructions</u>: For Program Services funded under this exhibit, the Network Provider shall report data under OCA: MH009 and shall adhere to the data coding instructions provided in the ME's Transition to Independence Process (TIP) Service Model policy and procedure.

<u>Section 6. Transition to Independence Process (TIP) model services monthly report</u>: Monthly Census and Waitlist Report – To ensure consistency and accuracy in monitoring service availability

and capacity, the Network Provider will submit the Children's System of Care Monthly Census and Waitlist Report in the template provided by the ME, by the 5<sup>th</sup> of each month following the month of service to the individual listed in Exhibit C, Required Reports.

<u>Section 7</u>. Contract funds may not be used, directly or indirectly, to purchase, prescribe, or provide marijuana or treatment using marijuana. Treatment in this context includes the treatment of opioid use disorder. Contract funds also cannot be provided to any individual who or organization that provides or permits marijuana use for the purposes of treating substance use or mental disorders. See, e.g., 45 C.F.R. §75.300 (a) (requiring HHS to "ensure that Federal funding is expended...in full accordance with U.S. statutory....requirements."); 21 U.S.C. §§ 812 (c) (10) and 841 (prohibiting the possession, manufacture, sale, purchase or distribution of marijuana). This prohibition does not apply to those providing such treatment in the context of clinical research permitted by the DEA and under an FDA-approved investigation new drug application where the article being evaluated is marijuana or a constituent thereof that is otherwise a banned controlled substance under federal law.